This is a Phase II/III trial across North America cooperative groups to study what kind of chemotherapy to recommend to low risk, Stage III colon cancer (T1-3, N1) patients based on the presence or absence of ctDNA after surgery for colon cancer.
SU2C: ctDNA-Guided FOLFIRI or Molecularly Directed Treatment
Scott Kopetz2025-09-22T19:30:40+00:00ctDNA positive patients randomized to FOLFIRI (12 cycles) or surveillance. If MSI-H, receive nivolumab (12 cycles). If BRAF mutation is present, receive encorafenib, binimetinib, and cetuximab (12 cycles).


